BioSpace News Archive

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright BioConnect 2021 Conference, held virtually from January 11-14 , 2021.

Pacific Neuroscience Institute is the first provider in the Providence health system to treat a patient with an innovative surgically implanted Deep Brain Stimulation device. Used for the mana

Ambulatory Surgery Center operators have a unique hybrid offering to leverage. Simplify ASC has announced it has completed its acquisition of PhyBus RCM, combining the latter’s revenue cycle management services with its proprietary EHR and Practice Management platform to create an operationally-focused solution for ASCs.

AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizumab (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscopic response at week 12 in adult patients with moderate to severe Crohn’s disease.

Integrated Oncology Network (ION), a nationwide leader in oncology and healthcare management services, and Southwest Urology, a market-leading urology practice, have announced a strategic partnership

Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced that specialty manufacturer Octapharma USA, Inc. has selected the Model N Revenue Management Cloud for Life Sciences, including Model N’s Provide

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, has been invited to present at H.C. Wainwright’s BioConnect 2021 Conference, being held virtually on January

RhoVac AB (“RhoVac”) announces today, on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company’s clinical phase IIb study in prostate cancer, a study named RhoVac-002 (“BRaVac”).

AstraZeneca vet Dr. David Wheadon joins board of managers, transformational leader Jim Corrigan appointed president

OncoDNA, a theranostic and genomic company specializing in precision oncology, has announced that it has signed a subcontract service agreement with HalioDx’s U.S.-based CLIA-certified laboratory located in Richmond, Virginia.